文献速递艾滋病与性传播感染

每日口服恩曲他滨/富马酸替诺福韦二吡呋酯进行HIV-1暴露前预防者中的1型人类免疫缺陷病毒(HIV-1)发病率、依从性与耐药性:72项全球研究的汇总分析

Type 1 Human Immunodeficiency Virus (HIV-1) Incidence, Adherence, and Drug Resistance in Individuals Taking Daily Emtricitabine/Tenofovir Disoproxil Fumarate for HIV-1 Pre-exposure Prophylaxis: Pooled Analysis From 72 Global Studies.
PubMed 文献 · Clin Infect Dis · 2024-01-01

该汇总分析纳入72项每日口服恩曲他滨/富马酸替诺福韦二吡呋酯(F/TDF)暴露前预防(PrEP)的前瞻性研究,共17 274名参与者,HIV-1发病率为0.77/100人年(95%CI:0.63-0.94)。在78例有耐药数据的病例中,23%携带M184I或V突变;在54例有干血斑替诺福韦浓度数据的病例中,83.3%平均依从性<2剂/周,相应发病率最高(3.9/100人年)。结论认为F/TDF安全且高效,即使非每日服药。

要点

  • 17 274名参与者中HIV-1发病率为0.77/100人年(95%CI:0.63-0.94)。
  • 78例耐药数据中18例(23%)有M184I或V,1例(1.3%)有K65R,3例(3.8%)两者均有。
  • 54例干血斑数据中平均依从性<2剂/周者占83.3%,其发病率为3.9/100人年。

核心结论

  • 基于迄今最大的全球PrEP研究汇总分析,F/TDF在不同临床环境、地理区域、人群和HIV-1暴露途径中安全且高效,即使服药频率低于每日一次。

研究设计与样本

  • 对72项每日口服F/TDF PrEP的前瞻性研究进行汇总分析,共纳入17 274名参与者;HIV-1发病率基于PrEP启动后至停药后60天内新诊断的HIV-1计算,并在部分研究中评估干血斑替诺福韦浓度、耐药性及骨/肾安全性指标。

主要发现

  • 17 274名参与者中,101例新诊断HIV-1,发病率为0.77/100人年(95%CI:0.63-0.94)。
  • 78例有耐药数据的病例中,18例(23%)有M184I或V,1例(1.3%)有K65R,3例(3.8%)同时有这两种突变。
  • 54例有干血斑替诺福韦浓度数据的病例中,平均依从性<2、2-3、4-6和≥7剂/周者分别占83.3%、3.7%、11.1%和1.9%,相应发病率分别为3.9(95%CI:2.9-5.3)、0.24(95%CI:0.060-0.95)、0.27(95%CI:0.12-0.60)和0.054(95%CI:0.008-0.38)/100人年。
  • 年轻参与者、西班牙裔/拉丁裔和黑人参与者、顺性别女性和跨性别女性的依从性较低。
  • 骨和肾不良事件发生率分别为0.69和11.8/100人年,与既往报告一致。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Oral pre-exposure prophylaxis (PrEP) with emtricitabine/tenofovir disoproxil fumarate (F/TDF) has high efficacy against HIV-1 acquisition. Seventy-two prospective studies of daily oral F/TDF PrEP were conducted to evaluate HIV-1 incidence, drug resistance, adherence, and bone and renal safety in diverse settings. METHODS: HIV-1 incidence was calculated from incident HIV-1 diagnoses after PrEP initiation and within 60 days of discontinuation. Tenofovir concentrations in dried blood spots (DBS), drug resistance, and bone/renal safety indicators were evaluated in a subset of studies. RESULTS: Among 17 274 participants, there were 101 cases with new HIV-1 diagnosis (.77 per 100 person-years; 95% confidence interval [CI]: .63-.94). In 78 cases with resistance data, 18 (23%) had M184I or V, 1 (1.3%) had K65R, and 3 (3.8%) had both mutations. In 54 cases with tenofovir concentration data from DBS, 45 (83.3%), 2 (3.7%), 6 (11.1%), and 1 (1.9%) had average adherence of <2, 2-3, 4-6, and ≥7 doses/wk, respectively, and the corresponding incidence was 3.9 (95% CI: 2.9-5.3), .24 (.060-.95), .27 (.12-.60), and .054 (.008-.38) per 100 person-years. Adherence was low in younger participants, Hispanic/Latinx and Black participants, cisgender women, and transgender women. Bone and renal adverse event incidence rates were 0.69 and 11.8 per 100 person-years, respectively, consistent with previous reports. CONCLUSIONS: Leveraging the largest pooled analysis of global PrEP studies to date, we demonstrate that F/TDF is safe and highly effective, even with less than daily dosing, in diverse clinical settings, geographies, populations, and routes of HIV-1 exposure.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Landovitz RJ, Tao L, Yang J, et al. Type 1 Human Immunodeficiency Virus (HIV-1) Incidence, Adherence, and Drug Resistance in Individuals Taking Daily Emtricitabine/Tenofovir Disoproxil Fumarate for HIV-1 Pre-exposure Prophylaxis: Pooled Analysis From 72 Global Studies. Clin Infect Dis. 2024. PMID: 38484128. doi:10.1093/cid/ciae143

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。